Autor Maksym Misichenko · Nasdaq ·
Co agenci AI myślą o tej wiadomości
Eli Lilly's selpercatinib (Retevmo) showed promising results in a Phase 3 trial, reducing recurrence risk by 83% in early-stage RET-positive NSCLC, potentially establishing it as the new standard of care. However, the market reaction was muted due to concerns about the small patient cohort, immature OS data, and potential liver toxicity.
Ryzyko: Immature OS data and potential liver toxicity may limit real-world adoption and peak sales, despite the strong EFS results.
Szansa: Expanding the addressable market into the earlier-stage, curative-intent setting and lengthening the duration of therapy per patient.
Analiza ta jest generowana przez pipeline StockScreener — cztery wiodące LLM (Claude, GPT, Gemini, Grok) otrzymują identyczne instrukcje z wbudowaną ochroną przed halucynacjami. Przeczytaj metodologię →
(RTTNews) - Eli Lilly and Co. (LLY) ogłosił wyniki z badania klinicznego fazy 3 LIBRETTO-432 Retevmo (selpercatinib) jako terapii doraźnej versus placebo u pacjentów z wczesnym stadium (IB-IIIA) RET fusion-positive nie-małego komórkowego raka płuc (NSCLC). Badanie spełniło swoje główne kryterium, wykazując wysoce istotną statystycznie i klinicznie istotną poprawę w szacowanym przez badaczy przeżyciu bez zdarzeń (EFS). Selpercatinib zmniejszył ryzyko nawrotu choroby lub zgonu o 83% w porównaniu do placebo w populacji analizy podstawowej.
Przy medianowym follow-up 24 miesięcy, szacowane przez badaczy EFS w populacji analizy podstawowej (pacjenci z stadium II-IIIA, n=109) było istotnie poprawione przy selpercatinib. Wskaźnik EFS po 24 miesiącach wynosił 92% dla selpercatinib versus 61% dla placebo. Mediana EFS nie została osiągnięta w grupie selpercatinib, w porównaniu do 31,8 miesięcy dla placebo. W całkowitej populacji badania (pacjenci z stadium IB-IIIA, n=151), wyniki były spójne, z wskaźnikiem EFS po 24 miesiącach 94% dla selpercatinib i 70% [95% CI, 55,5-80,1] dla placebo. Wyniki były zgodne z oceną ślepej niezależnej centralnej recenzji i kluczowymi podgrupami zarówno w populacji podstawowej, jak i całkowitej. Wyniki całkowitego przeżycia (OS) skłoniły się na korzyść selpercatinib, choć dane były niedojrzałe w momencie analizy z niewielką liczbą zdarzeń.
Profil bezpieczeństwa selpercatinib w LIBRETTO-432 był ogólnie zgodny z poprzednimi badaniami w jego programie rozwojowym. Najczęstsze zdarzenia niepożądane stopnia 3 lub wyższego to zwiększone alanine aminotransferase (ALT) (17% vs. 1% z placebo) i zwiększone aspartate aminotransferase (AST) (19% vs. 3% z placebo). Te zdarzenia były zarządzalne dzięki modyfikacjom dawek, co wspiera ogólną tolerowalność selpercatinib w tym ustawieniu.
LLY zamknęło się na poziomie $1,105.00, spadając o $21.80 lub 1,93% 29 maja o 4:04:50 PM EDT. W handlu po godzinach, akcja nieco dalej spadła do $1,103.63, spadając o $1.38 lub 0,12%.
Aby uzyskać więcej takich wiadomości zdrowotnych, odwiedź rttnews.com.
Poglądy i opinie wyrażone tutaj są poglądami i opiniami autora i nie muszą odzwierciedlać poglądów i opinii Nasdaq, Inc.
Cztery wiodące modele AI dyskutują o tym artykule
"LIBRETTO-432 meaningfully widens Retevmo's addressable NSCLC population despite the niche RET+ segment."
Eli Lilly's 83% EFS risk reduction in stage II-IIIA RET+ NSCLC with selpercatinib marks a clear label-expansion win into adjuvant use, where current options are limited. The 92% vs 61% 24-month EFS gap in the primary population and consistent subgroup results suggest durable benefit, while liver enzyme elevations appear dose-manageable. At $1,105, LLY's valuation already prices in oncology leadership, so this data could support modest re-rating if regulators view the immature OS favorably. RET fusions occur in only 1-2% of NSCLC cases, capping peak sales upside relative to broader TKIs. Follow-up data and full approval timeline will determine whether this moves the needle beyond incremental growth.
The 109-patient primary cohort and immature OS leave room for later divergence or narrower labeling, while the 1-2% RET+ incidence may keep this from becoming a major revenue driver given LLY's existing scale.
"Strong efficacy signal in a small population is offset by immature OS data, limited market size (~500-800 eligible US patients annually), and hepatotoxicity concerns that could constrain uptake in adjuvant therapy where tolerability thresholds are higher than metastatic settings."
LIBRETTO-432 is a genuinely strong Phase 3 result—83% recurrence risk reduction with 92% vs 61% 24-month EFS is clinically meaningful in early-stage NSCLC. But the market's muted reaction (LLY down 1.93% on announcement day) suggests investors are pricing in three headwinds: (1) RET+ NSCLC is rare (~3-5% of NSCLC cases), limiting addressable market; (2) OS data immature with few events—EFS doesn't always translate to survival benefit; (3) liver enzyme elevation (17-19% Grade 3+) requires monitoring and may limit real-world adoption in adjuvant settings where patients are often asymptomatic. The 24-month follow-up is also relatively short for adjuvant oncology claims.
If OS data ultimately shows no significant benefit (or narrower benefit than EFS suggests), this becomes a label expansion for a niche indication that doesn't move LLY's needle materially—and the stock's flat reaction may have already priced that risk in.
"LIBRETTO-432 validates Retevmo's shift into the lucrative adjuvant setting, providing a long-term competitive advantage in the precision oncology space."
The 83% reduction in recurrence risk is a clinical home run, effectively establishing Retevmo as the new standard of care for adjuvant RET-positive NSCLC. For LLY, this expands the addressable market from late-stage metastatic patients into the earlier-stage, curative-intent setting, significantly lengthening the duration of therapy and revenue capture per patient. However, the market reaction was muted. Investors are likely looking past this win, focusing instead on the high cost of goods and the competitive threat from Roche’s Gavreto or potential next-gen TKIs. While this reinforces LLY’s oncology moat, the stock’s premium valuation requires consistent, massive growth, and this niche indication—though high-margin—won't move the needle on LLY’s massive $1T+ market cap alone.
The liver toxicity profile (17-19% Grade 3+ ALT/AST elevation) is non-trivial for an adjuvant setting where patients are otherwise healthy, potentially limiting real-world uptake due to strict monitoring requirements.
"Durable OS confirmation is essential for real upside; until then, the result is a promising but unproven advancement."
Strong Phase 3 signal for Retevmo in adjuvant RET fusion NSCLC with 83% reduced risk of recurrence (HR ~0.17) and 24-month EFS at 92% vs 61% in II-IIIA, suggesting potential to upend the RET+ subset of resected NSCLC if OS follows. However, the endpoint is EFS, not OS, and the OS data are immature. The primary analysis sample is small (n=109; stage II-IIIA) and the overall population also modest (n=151), raising questions about durability and generalizability. Safety shows hepatotoxicity risk (ALT/AST Grade ≥3) that could affect adherence in adjuvant settings. Real-world adoption will hinge on durable OS benefit, cost, and how it compares to existing adjuvant approaches.
OS is immature and may fail to improve; this EFS lead may not translate to meaningful survival or quality-of-life gains in the adjuvant setting, especially with a small, potentially non-generalizable sample.
"RET+ incidence closer to 1-2% than 3-5% further caps any revenue impact from this niche expansion."
Claude's 3-5% RET+ incidence overstates the market; Grok's 1-2% figure matches published NSCLC fusion rates and shrinks the addressable pool further. Even with clean EFS, this keeps peak sales incremental at LLY's scale, especially when paired with the n=109 primary cohort that will slow post-approval real-world data collection and payer confidence.
"Adjuvant oncology revenue is frontloaded and finite per patient, not a durable revenue stream like metastatic care—this structural limit matters more than incidence rates."
Grok and Claude are debating incidence (1-2% vs 3-5%), but both miss the real issue: even if we accept 1-2%, adjuvant NSCLC stages II-IIIA represent ~40% of all RET+ cases diagnosed annually. The market isn't small—it's *concentrated and front-loaded*. Patients get one adjuvant course, then remission surveillance. This isn't chronic dosing like metastatic disease. Peak sales upside is capped not by prevalence but by treatment duration per patient.
"Adjuvant success creates a revenue paradox by shrinking the future pool of high-margin metastatic patients."
Claude is right about the front-loaded nature of adjuvant therapy, but both Claude and Gemini ignore the competitive displacement risk. If Retevmo becomes the standard of care, it isn't just capturing new patients; it’s cannibalizing the metastatic-line market by preventing progression in the first place. The real risk isn't the small patient pool—it’s that LLY is effectively shrinking their own long-term, high-revenue metastatic patient base by successfully curing them early.
"OS durability and safety in the adjuvant setting will determine real-world uptake; without a proven OS benefit, hepatotoxicity and monitoring burdens could cap adoption and peak sales."
Responding to Claude: the front-loaded, high-margin adjuvant argument hinges on durable OS, not EFS. The key flaw is assuming a clean OS uplift will follow. In adjuvant NSCLC, 17-19% Grade 3 ALT/AST toxicity plus monitoring burdens risk adherence and real-world uptake, especially if events are sporadic and OS remains immature. Until OS is proven, payer/care pathways may constrict adoption, capping peak sales regardless of a large upfront addressable pool.
Eli Lilly's selpercatinib (Retevmo) showed promising results in a Phase 3 trial, reducing recurrence risk by 83% in early-stage RET-positive NSCLC, potentially establishing it as the new standard of care. However, the market reaction was muted due to concerns about the small patient cohort, immature OS data, and potential liver toxicity.
Expanding the addressable market into the earlier-stage, curative-intent setting and lengthening the duration of therapy per patient.
Immature OS data and potential liver toxicity may limit real-world adoption and peak sales, despite the strong EFS results.